Ambroxol Hydrochloride
(Responsible Entity Logo)
Ambroxol Hydrochloride, the Active Substance of Mucosolvan Inhalations, Increases the Secretion of Mucus in the Airways, Making it Easier to Cough Up and Relieving Cough.
Indications for Use
Acute and Chronic Lung and Bronchial Diseases Characterized by Impaired Mucus Secretion and its Transport.
Tell Your Doctor About all Medicinal Products You are Currently Taking or Have Recently Taken, as well as any Medicinal Products You Plan to Take.
No Clinically Significant Adverse Interactions with Other Medicinal Products have been Observed.
Ambroxol Increases the Concentration of Antibiotics (Amoxicillin, Cefuroxime, Erythromycin) in Bronchopulmonary Secretions and Sputum.
Mucosolvan Inhalations Should not be Administered Simultaneously with Cough Suppressants (e.g., Codeine), as this may Lead to Dangerous Accumulation of Bronchial Secretions due to Weakened Cough Reflex. Cough Suppressants, by Inhibiting the Cough Reflex, Make it Difficult to Cough Up the Thinned Mucus.
If You are Pregnant or Breastfeeding, Think You may be Pregnant or are Planning to Have a Child, Consult Your Doctor or Pharmacist Before Using this Medicinal Product.
The Use of Mucosolvan Inhalations is not Recommended During Pregnancy, Especially During the First Trimester.
The Use of Mucosolvan Inhalations is not Recommended in Breastfeeding Women, as Ambroxol Hydrochloride Passes into Breast Milk.
Non-Clinical Studies have not Shown any Direct or Indirect Harmful Effects on Fertility. There are no Clinical Studies on the Effects on Fertility.
There is no Evidence that the Medicinal Product Affects the Ability to Drive and Use Machines.
No Studies have been Conducted on the Effects of the Medicinal Product on the Ability to Drive and Use Machines.
The Medicinal Product Contains 0.45 mg of Benzalkonium Chloride per 2 ml of Solution.
Benzalkonium Chloride may Cause Wheezing (Whistling Breathing) or Respiratory Disturbances (Bronchospasm), Especially in Patients with Asthma.
The Medicinal Product Contains Less than 1 mmol (23 mg) of Sodium per 3 ml of Solution, i.e., the Medicinal Product is Considered "Sodium-Free".
This Medicinal Product Should Always be Used in Accordance with the Doctor's Recommendations. In Case of Doubts, Consult a Doctor or Pharmacist.
Recommended Dose:
Adults, Children Over 6 Years of Age:
1 to 2 Inhalations of 2 to 3 ml of Solution per Day.
Children Under 6 Years of Age:
1 to 2 Inhalations of 2 ml of Solution per Day.
It is Recommended to Warm the Nebuliser Solution to Body Temperature Before Starting Inhalation.
Patients with Asthma may Take the Inhalation Solution After Taking their Usual Bronchodilators.
To Ensure Proper Functioning of the Dropper, Turn the Bottle Upside Down and Gently Tap it.
Mucosolvan Inhalations can be Administered Using any Modern Inhaler (Except Steam). The Nebuliser Solution can be Mixed with Physiological Saline (0.9% Sodium Chloride Solution) in a 1:1 Ratio to Optimize Air Humidification, Especially When Using a Respirator. Mucosolvan Inhalations Should not be Mixed with Cromoglycic Acid. The Medicinal Product Should also not be Mixed with Other Solutions that Result in a Solution with a pH Higher than 6.3, e.g., Alkaline Salt Water for Inhalation (Soll's Salt). Due to the Increased pH, a Precipitate of Free Ambroxol Hydrochloride or Clouding of the Solution may Occur.
The Patient Should Breathe Normally During Inhalation, as the Inhalation of the Solution itself may Cause a Cough Reflex.
Do not Use the Medicinal Product Before Going to Bed.
In Case of Using a Higher Dose of Mucosolvan Inhalations than Recommended, Consult a Doctor or Pharmacist.
No Specific Symptoms of Overdose of the Medicinal Product have been Observed in Humans. Based on Cases of Accidental Overdose and/or Reports of Incorrect Use, Symptoms Corresponding to the Known Adverse Reactions of the Medicinal Product at Recommended Doses have been Observed. Symptomatic Treatment may be Necessary.
If a Dose is Missed, Take it as Soon as Possible.
Do not Take a Double Dose to Make up for the Missed Dose. The Next Dose Should be Taken at the Usual Time.
Mucosolvan Inhalations Should be Used Only When Necessary, and its Use Should be Stopped After the Symptoms Have Disappeared.
In Case of any Further Doubts Regarding the Use of this Medicinal Product, Consult a Doctor or Pharmacist.
Like all Medicinal Products, this Medicinal Product can Cause Side Effects, although not Everybody gets them.
The Following Adverse Reactions have been Reported:
If You Experience any Side Effects, including those not Listed in this Package Leaflet, Tell Your Doctor, Pharmacist, or Nurse. Side Effects can be Reported Directly to the Department for Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products: Al. Jerozolimskie 181C, 02-222 Warsaw; Tel: +48 22 492 13 01; Fax: +48 22 492 13 09; Website: https://smz.ezdrowie.gov.pl
Side Effects can also be Reported to the Marketing Authorisation Holder. By Reporting Side Effects, You can Help Provide More Information on the Safety of this Medicinal Product.
There are no Special Precautions for Storage.
Keep this Medicinal Product out of the Sight and Reach of Children.
Do not Use this Medicinal Product After the Expiry Date Stated on the Bottle and Carton. The Expiry Date Refers to the Last Day of the Month Stated.
The Shelf Life After First Opening the Bottle is 12 Months.
Medicinal Products Should not be Disposed of via Wastewater or Household Waste. Ask Your Pharmacist How to Dispose of Medicinal Products that are no Longer Needed. This will Help Protect the Environment.
The Package Consists of 1 Bottle Containing 100 ml of Nebuliser Solution.
Marketing Authorisation Holder:
Opella Healthcare Poland Sp. z o.o.
ul. Marcina Kasprzaka 6
01-211 Warsaw
Manufacturer:
Istituto de Angeli S.r.l.
Loc. Prulli, 103/C
50066 Reggello (FI)
Italy
For Further Information on this Medicinal Product, Please Contact:
Opella Healthcare Poland Sp. z o.o.
ul. Marcina Kasprzaka 6
01-211 Warsaw
Tel.: +48 22 280 00 00
Date of Last Revision of the Package Leaflet:April 2024
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.